首页> 中国专利> PGB基因变体在增加癌症化疗药物敏感度中的应用

PGB基因变体在增加癌症化疗药物敏感度中的应用

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明本发明首次公开了PGB基因可以用于制备肿瘤细胞化疗增敏药物，有助于提高癌细胞对极低浓度的化疗药物顺铂的敏感性，增强化疗药物的疗效，提高肿瘤患者的生命质量，在肿瘤治疗领域具有潜在、良好的应用前景。所述PGB变体基因，其核苷酸序列如SEQ ID NO.1所示。

著录项

公开/公告号CN106754955A

专利类型发明专利
公开/公告日2017-05-31

原文格式PDF
申请/专利权人石佳明;
展开▼

申请/专利号CN201611070069.7
发明设计人石佳明;
展开▼

申请日2016-11-29
分类号C12N15/29(20060101);C12N15/63(20060101);A61K48/00(20060101);A61P35/00(20060101);
代理机构
代理人
地址 054200 河北省邢台市内丘县大孟镇北良村274号
入库时间 2023-06-19 02:23:20

法律信息

法律状态公告日

法律状态信息

法律状态
2017-06-23

实质审查的生效 IPC(主分类):C12N15/29 申请日:20161129

实质审查的生效
2017-05-31

公开

公开

相似文献

专利
中文文献
外文文献

1. PGB基因变体在增加癌症化疗药物敏感度中的应用 [P] . 中国专利： CN106754955A . 2017-05-31
2. 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 [P] . 中国专利： CN101073665B . 2014.11.26
3. isolated polynucleotide, expression cassette, host cell, isolated polypeptide, non-human transgenic animal that has been altered to express an alkali resistant mutant polypeptide, an antibody that specifically binds to an alkali resistant mutant polypeptide, a mutation detection kit alk inhibitor resistance in a biological sample, and methods for evaluating a biological sample for an alk inhibitor resistance mutation to diagnose cancer that is resistant to or likely to develop resistance to at least one alkaline inhibitor. small alk molecule kinase, to evaluate a biological sample for an alk inhibitor resistance mutation, to diagnose cancer that is resistant to or likely to develop resistance to pf-02341066 in a patient, to specifically reduce expression of an alk-resistant mutant to treat cancer associated with activating aberrant loop capacity that is resistant to at least one small molecule alk kinase inhibitor treating an aberrant cancer that is resistant to pf-02341066, identifyin [P] . BR112012026239A2 . 2018-06-26

机译：分离的多核苷酸，表达盒，宿主细胞，分离的多肽，已被改变以表达耐碱突变体多肽的非人类转基因动物，与耐碱突变体多肽特异性结合的抗体，突变检测试剂盒生物样品，以及用于评估生物样品中是否存在对烷基抑制剂的抗性突变以诊断对至少一种碱性抑制剂有抗药性或可能发展出抗药性的癌症的方法。小分子激酶，用于评估生物学样品中是否具有抑制碱性磷酸酶抑制剂的突变，以诊断对患者具有抗药性或可能对pf-02341066产生抗药性的癌症，从而特异性降低抗癌突变体的表达以治疗癌症与激活抗至少一种小分子烷基激酶抑制剂的异常环路能力有关，该抑制剂治疗对pf-02341066有抵抗力的异常癌症
4. Polinucleotu00eddeo insulated tape of expression, host cell, isolated transgenic non-human animal polypeptide, which has been modified to express a polypeptide mutant with resistance to ALK, antibody that binds specifically to a polypeptide mutant with resistance to ALK, kit p For detection of a mutation with resistance to ALK inhibitor in a biological sample, and,Methods for evaluating a biological sample as a mutation with resistance to ALK inhibitor, for diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to evaluate a biological sample that Anto a mutation with resistance to ALK inhibitor.For diagnosing a cancer that is resistant to or is likely to develop resistance to at least one inhibitor of kinase small molecule ALK, to assess the biological sample as a mutation with resistance to ALK inhibitor, a cancer that is resistant to dianosticar Or is likely to develop resistance to PF - 02341066 in a pati [P] . BR112012026239A2 . 2016-11-29

机译：修饰的多聚核苷酸绝缘带，宿主细胞，分离的转基因非人类动物多肽，经过修饰以表达对ALK具有抗性的多肽突变体，与对ALK具有抗性的多肽突变体特异性结合的抗体，试剂盒p用于检测生物样品中对ALK抑制剂具有抗性的突变，以及用于评估生物样品为对ALK抑制剂具有抗性的突变的方法，用于诊断对至少一种对ALK抑制剂具有抗性或可能发展出抗性的癌症激酶小分子ALK，以评估Anto对ALK抑制剂具有抗性的突变的生物样品。用于诊断对至少一种激酶小分子ALK抑制剂具有抗药性或可能产生抗性的癌症，以评估该生物样品作为对ALK抑制剂有抗性的突变，即对狄诺司他抗性或可能对PF产生抗药性的癌症-02341066
5. HSP110 mutant negative dominant and its use in the prognosis and treatment of cancers [P] . ES2575980T3 . 2016-07-04

机译： HSP110突变体阴性显性基因及其在癌症预后中的应用